Aktis Oncology (NASDAQ:AKTS) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Aktis Oncology (NASDAQ:AKTS) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Several other research firms have also recently weighed in on AKTS. Raymond James Financial initiated coverage on Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 target price on the stock. JPMorgan Chase & Co. raised their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. William Blair began coverage on shares of Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating on the stock. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Finally, HC Wainwright increased their target price on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.60.

Aktis Oncology Price Performance

AKTS opened at $23.89 on Friday. The stock has a market capitalization of $1.28 billion and a price-to-earnings ratio of -62.87. The firm has a fifty day simple moving average of $23.87. Aktis Oncology has a 12-month low of $14.72 and a 12-month high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The firm had revenue of $3.23 million during the quarter, compared to analyst estimates of $2.23 million. On average, equities analysts expect that Aktis Oncology will post -1.64 earnings per share for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.